Citations (24)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
M Pfeiffer-Jensen, D Liao, U Tarp, B Deleuran, K Stengaard-Pedersen, J Venborg, B Brock & C Brock. (2023) Reduced prescription of TNF-inhibitors in chronic arthritis based on therapeutic drug monitoring: A randomized controlled trial. Scandinavian Journal of Rheumatology 52:5, pages 468-480.
Read now
Read now
David T. Rubin, Snehal Naik, Venkateswarlu Kondragunta, Tharak Rao & Anjali Jain. (2017) Detection of adalimumab and antibodies to adalimumab using a homogeneous mobility shift assay. Current Medical Research and Opinion 33:5, pages 837-843.
Read now
Read now
Irene D. Román, David Cano-Martínez, María Val T. Lobo, María Dolores Fernández-Moreno, Borja Hernández-Breijo, Silvia Sacristán, Patricia Sanmartín-Salinas, Jorge Monserrat, Javier P. Gisbert & Luis G. Guijarro. (2017) Infliximab therapy reverses the increase of allograft inflammatory factor-1 in serum and colonic mucosa of rats with inflammatory bowel disease. Biomarkers 22:2, pages 133-144.
Read now
Read now
Virginia Martínez-Santana, E González-Sarmiento, MA Calleja-Hernández & T Sánchez-Sánchez. (2013) Comparison of drug survival rates for tumor necrosis factor antagonists in rheumatoid arthritis. Patient Preference and Adherence 7, pages 719-727.
Read now
Read now
Vera Kandror Denmark & Lloyd Mayer. (2013) Current status of monoclonal antibody therapy for the treatment of inflammatory bowel disease: an update. Expert Review of Clinical Immunology 9:1, pages 77-92.
Read now
Read now
Tim L Jansen & CJJ Mulder. (2012) Rheumatology meets hepatology in 2012: a clinician's guideline for TNF inhibitors in hepatitis B/C virus carriers. Expert Opinion on Biological Therapy 12:4, pages 391-393.
Read now
Read now
Articles from other publishers (18)
Judith Anne Murphy. (2018) Biologics and biosimilars in inflammatory bowel disease. Nurse Prescribing 16:Sup7, pages 14-18.
Crossref
Crossref
Obinna C. Ubah, John Steven, Marina Kovaleva, Laura Ferguson, Charlotte Barelle, Andrew J. R. Porter & Caroline J. Barelle. (2017) Novel, Anti-hTNF-α Variable New Antigen Receptor Formats with Enhanced Neutralizing Potency and Multifunctionality, Generated for Therapeutic Development. Frontiers in Immunology 8.
Crossref
Crossref
Judith Anne Murphy. (2017) Getting the best out of biological and biosimilar medicines for inflammatory bowel disease. Gastrointestinal Nursing 15:5, pages 16-23.
Crossref
Crossref
Maria Dolores Martin-Arranz. (2016) Monitoring Anti-Tnf Drug Treatment in Inflammatory Bowel Disease. Is it Useful in Clinical Practice?. Gastroenterology & Hepatology: Open Access 5:6.
Crossref
Crossref
Yi Li, Luca Stocchi, Yuanyi Rui, Feza H. Remzi & Bo Shen. (2016) Comparable outcomes of the consistent use versus switched use of anti- tumor necrosis factor agents in postoperative recurrent Crohn’s disease following ileocolonic resection. International Journal of Colorectal Disease 31:11, pages 1751-1758.
Crossref
Crossref
Phillip Minar, Shehzad A. Saeed, Mahrukh Afreen, Mi-Ok Kim & Lee A. Denson. (2016) Practical Use of Infliximab Concentration Monitoring in Pediatric Crohn Disease. Journal of Pediatric Gastroenterology & Nutrition 62:5, pages 715-722.
Crossref
Crossref
Vipul Yadav, Felipe Varum, Roberto Bravo, Esther Furrer & Abdul W. Basit. (2016) Gastrointestinal stability of therapeutic anti-TNF α IgG1 monoclonal antibodies. International Journal of Pharmaceutics 502:1-2, pages 181-187.
Crossref
Crossref
Aoibhlinn O’Toole & Alan C. Moss. (2015) Optimizing Biologic Agents in Ulcerative Colitis and Crohn’s Disease. Current Gastroenterology Reports 17:8.
Crossref
Crossref
Xiaoyun Peng, Boning Liu, Yantao Li, Hui Wang, Xi Chen, Huaizu Guo, Qingcheng Guo, Jin Xu, Hao Wang, Dapeng Zhang, Jianxin Dai, Sheng Hou & Yajun Guo. (2015) Development and Validation of LC–MS/MS Method for the Quantitation of Infliximab in Human Serum. Chromatographia 78:7-8, pages 521-531.
Crossref
Crossref
Sung Chul Park & Yoon Tae Jeen. (2015) Current and Emerging Biologics for Ulcerative Colitis. Gut and Liver 9:1, pages 18-27.
Crossref
Crossref
F.M. Ruemmele, G. Veres, K.L. Kolho, A. Griffiths, A. Levine, J.C. Escher, J. Amil Dias, A. Barabino, C.P. Braegger, J. Bronsky, S. Buderus, J. Martín-de-Carpi, L. De Ridder, U.L. Fagerberg, J.P. Hugot, J. Kierkus, S. Kolacek, S. Koletzko, P. Lionetti, E. Miele, V.M. Navas López, A. Paerregaard, R.K. Russell, D.E. Serban, R. Shaoul, P. Van Rheenen, G. Veereman, B. Weiss, D. Wilson, A. Dignass, A. Eliakim, H. Winter & D. Turner. (2014) Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease. Journal of Crohn's and Colitis 8:10, pages 1179-1207.
Crossref
Crossref
Geert R. D'Haens, R. Balfour Sartor, Mark S. Silverberg, Joel Petersson & Paul Rutgeerts. (2014) Future directions in inflammatory bowel disease management. Journal of Crohn's and Colitis 8:8, pages 726-734.
Crossref
Crossref
Reena Khanna & Brian G. Feagan. (2014) Current and Future Status of Therapeutic Drug Monitoring in the Treatment of IBD. Current Treatment Options in Gastroenterology 12:1, pages 76-89.
Crossref
Crossref
R. Khanna, B. D. Sattin, W. Afif, E. I. Benchimol, E.-J. Bernard, A. Bitton, B. Bressler, R. N. Fedorak, S. Ghosh, G. R. Greenberg, J. K. Marshall, R. Panaccione, E. G. Seidman, M. S. Silverberg, A. H. Steinhart, R. Sy, G. Van Assche, T. D. Walters, W. J. Sandborn & B. G. Feagan. (2013) Review article: a clinician's guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease. Alimentary Pharmacology & Therapeutics 38:5, pages 447-459.
Crossref
Crossref
Paul L. A. M. Corstjens, Herma H. Fidder, Karien C. Wiesmeijer, Claudia J. de Dood, Theo Rispens, Gert-Jan Wolbink, Daniel W. Hommes & Hans J. Tanke. (2013) A rapid assay for on-site monitoring of infliximab trough levels: a feasibility study. Analytical and Bioanalytical Chemistry 405:23, pages 7367-7375.
Crossref
Crossref
Shui-Long Wang, Scott Hauenstein, Linda Ohrmund, Reshma Shringarpure, Jared Salbato, Rukmini Reddy, Kevin McCowen, Shawn Shah, Steven Lockton, Emil Chuang & Sharat Singh. (2013) Monitoring of adalimumab and antibodies-to-adalimumab levels in patient serum by the homogeneous mobility shift assay. Journal of Pharmaceutical and Biomedical Analysis 78-79, pages 39-44.
Crossref
Crossref
T. Molnár, P. L. Lakatos, K. Farkas, F. Nagy, Z. Szepes, P. Miheller, G. Horváth, M. Papp, K. Palatka, T. Nyári, A. Bálint, K. Lőrinczy & T. Wittmann. (2012) Predictors of relapse in patients with Crohn's disease in remission after 1 year of biological therapy. Alimentary Pharmacology & Therapeutics 37:2, pages 225-233.
Crossref
Crossref
Shui-Long Wang, Linda Ohrmund, Scott Hauenstein, Jared Salbato, Rukmini Reddy, Patrick Monk, Steven Lockton, Nicholas Ling & Sharat Singh. (2012) Development and validation of a homogeneous mobility shift assay for the measurement of infliximab and antibodies-to-infliximab levels in patient serum. Journal of Immunological Methods 382:1-2, pages 177-188.
Crossref
Crossref